

PREVALENCE OF TUBERCULOSIS IN SUB-SAHARAN AFRICA

Brooke Heaton

FOOTNOTES

1. *Oxford English Dictionary, 2nd ed.* (Oxford: Oxford University Press, 2004), s.v. "Malnutrition."
2. *Oxford English Dictionary, 2nd ed.* (Oxford: Oxford University Press, 2004), s.v. "Morbidity."
3. *Oxford English Dictionary, 2nd ed.* (Oxford: Oxford University Press, 2004), s.v. "Sub-Saharan Africa."
4. *Oxford English Dictionary, 2nd ed.* (Oxford: Oxford University Press, 2004), s.v. "Tuberculosis."
5. "Global Tuberculosis Report 2020," World Health Organization 2020, Accessed January 21, 2021, <https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf>.
6. "The Difference Between Latent TB Infection and TB Disease," National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Center for Disease Control, Accessed January 21, 2022, <https://www.cdc.gov/tb/publications/factsheets/general/lbtbiandactivetb.pdf>.
7. "How TB Spreads," Centers for Disease Control and Prevention, Accessed January 21, 2021, <https://www.cdc.gov/tb/topic/basics/howtbspreads.htm>.
8. "The Difference Between Latent TB Infection and TB Disease," National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Center for Disease Control, Accessed January 21, 2022, <https://www.cdc.gov/tb/publications/factsheets/general/lbtbiandactivetb.pdf>.
9. Adam Cohen et al., "The Global Prevalence Of Latent Tuberculosis: A Systematic Review And Meta-Analysis," *European Respiratory Journal* 54, no. 3 (2019), <https://doi.org/10.1183/13993003.00655-2019>.
10. Takele Tadesse et al., "Two-Thirds Of Smear-Positive Tuberculosis Cases In The Community Were Undiagnosed In Northwest Ethiopia: Population Based Cross-Sectional Study," *PLOS One*, December 2, 2011, <https://doi.org/10.1371/journal.pone.0028258>.
11. Ninfa Marlen et al., "Factors Predictive Of The Success Of Tuberculosis Treatment: A Systematic Review With Meta-Analysis," *PLOS One*, December 27, 2019, <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0226507>.
12. "Treatment for TB Disease," Centers for Disease Control and Prevention, Accessed August 15, 2021, <https://www.cdc.gov/tb/topic/treatment/tbdisease.htm>.
13. "Treatment Tuberculosis (TB)," National Health Service, Accessed August 15, 2021, <https://www.nhs.uk/conditions/tuberculosis-tb/treatment/>.
14. "Tuberculosis(TB) Fact Sheet," World Health Organization, Accessed March 27, 2021, <https://www.afro.who.int/health-topics/tuberculosis-tb>.
15. "Treatment Tuberculosis (TB)," National Health Service, Accessed August 15, 2021, <https://www.nhs.uk/conditions/tuberculosis-tb/treatment/>.
16. Zumla, Alimuddin Zumla et al., "Tackling the Tuberculosis Epidemic in Sub-Saharan Africa – Unique Opportunities Arising from the Second European Developing Countries Clinical Trials Partnership (EDCTP) Programme 2015-2024," *International Journal of Infectious Diseases* 32, (March 2015): 46-49, <https://www.clinicalkey.es/playcontent/1-s2.0-S1201971214017573>.
17. Tamara Davenne and Helen McShane, "Why Don't We Have an Effective Tuberculosis Vaccine Yet?," *Expert Review of Vaccines* 15, no. 8 (May 3, 2016): 1009-1013, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950406/>.
18. "TB Risk Factors," Centers for Disease Control and Prevention, Accessed January 21, 2021, <https://www.cdc.gov/tb/topic/basics/risk.htm>.
19. Ibid.

20. "Levels and Trends in Child Mortality 2012," UNICEF, Accessed January 22, 2022, <https://data.unicef.org/resources/levels-trends-child-mortality-report-2012/>.
21. JM Grange and A. Zumla, "The Global Emergency Of Tuberculosis: What Is The Cause?," *Journal of the Royal Society for the Promotion of Health*, (2002), Accessed January 27, 2021, <https://doi.org/10.1177/146642400212200206>.
22. "Tuberculosis(TB) Fact Sheet," World Health Organization, Accessed March 27, 2021, <https://www.afro.who.int/health-topics/tuberculosis-tb>.
23. "Tuberculosis Key Facts," World Health Organization, Accessed March 27, 2021, <https://www.who.int/news-room/fact-sheets/detail/tuberculosis>.
24. Mengistu Legesse et al., "Community-Based Cross-Sectional Survey Of Latent Tuberculosis Infection In Afar Pastoralists, Ethiopia, Using Quantiferon-Tb Gold In-Tube And Tuberculin Skin Test," *BioMed Central*, April 9, 2011, <https://doi.org/10.1186/1471-2334-11-89>.
25. Florence N Kizza et al., "Prevalence Of Latent Tuberculosis Infection And Associated Risk Factors In An Urban African Setting," *BioMed Central*, March 29, 2015, <https://doi.org/10.1186/s12879-015-0904-1>.
26. "Global Health Observatory Data Repository," World Health Organization, Accessed January 22, 2022, <https://apps.who.int/gho/data/view.main.57020ALL?lang=en>.
27. "Standard Country or Area Codes for Statistical Use," United Nations, Statistics Division, Accessed January 27, 2021, <https://unstats.un.org/unsd/methodology/m49/>.
28. "World TB Day 2021." Centers for Disease Control and Prevention. Accessed January 27, 2022, <https://www.cdc.gov/tb/worldtbdays/history.htm#:~:text=On%20March%2024%2C%201882%2C%20Dr,the%20United%20States%20and%20Europe>.
29. "Incidence of Tuberculosis (Per 100,000 People) - Sub-Saharan Africa World Health Organization, Global Tuberculosis Report, The World Bank, Accessed January 27, 2022, <https://data.worldbank.org/indicator/SH.TBS.INCD?end=2019&locations=ZG&start=2000>.
30. Ibid.
31. Nicola M. Zetola et al., "Population-Based Geospatial And Molecular Epidemiologic Study Of Tuberculosis Transmission Dynamics, Botswana, 2012-2016." *Emerging Infectious Diseases* 27, no.3 (March 2021): 835-844, <https://doi.org/10.3201/eid2703.203840>.
32. "Population Density in Africa as of 2020, by Country," United Nations, Accessed January 22, 2022, <https://www.statista.com/statistics/1218003/population-density-in-africa-by-country/>.
33. "2020 Census Apportionment Results". The United States Census Bureau, Accessed April 27, 2021, <https://www.census.gov/data/tables/2020/dec/2020-apportionment-data.html>.
34. "Africa: Demographic Patterns," *Britannica Encyclopedia*, accessed January 21, 2022, <https://www.britannica.com/place/Africa/Demographic-patterns>.
35. Steven Russell, "The Economic Burden Of Illness For Households In Developing Countries: A Review Of Studies Focusing On Malaria, Tuberculosis, And Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome," *The American Journal of Tropical Medicine and Hygiene* 71, no. 2, (January 2004): 147-155, <https://doi.org/10.4269/ajtmh.2004.71.147>.
36. Nicola M. Zetola et al., "Population-Based Geospatial And Molecular Epidemiologic Study Of Tuberculosis Transmission Dynamics, Botswana, 2012-2016." *Emerging Infectious Diseases* 27, no.3 (March 2021): 835-844, <https://doi.org/10.3201/eid2703.203840>.
37. Robin Wood et al., "Indoor Social Networks in a South African Township: Potential Contribution of Location to Tuberculosis Transmission," *PLOS ONE* 7, no. 6 (June 29, 2012), <https://doi.org/10.1371/journal.pone.0039246>.
38. Nicky McCreesh and Richard G. White, "An Explanation For The Low Proportion Of Tuberculosis That Results From Transmission Between Household And Known Social Contacts," *Scientific Reports*, March 29, 2018, <https://www.nature.com/articles/s41598-018-23797-2.pdf>.

39. "Tuberculosis (TB) Fact Sheet," World Health Organization, Accessed March 27, 2021, <https://www.afro.who.int/health-topics/tuberculosis-tb>.
40. Mario Raviglione et al., "Scaling up Interventions to Achieve Global Tuberculosis Control: Progress and New Developments," *The Lancet* 379, no. 9829 (June 15, 2012): 1902-1913, [https://doi.org/10.1016/s0140-6736\(12\)60727-2](https://doi.org/10.1016/s0140-6736(12)60727-2).
41. "Tuberculosis (TB) Fact Sheet," World Health Organization, Accessed March 27, 2021, <https://www.afro.who.int/health-topics/tuberculosis-tb>.
42. Ibid.
43. Nathan Kapata et al., "The Prevalence Of Tuberculosis In Zambia: Results From The First National Tb Prevalence Survey, 2013-2014," *PLOS One*, 11, no.1 (January 15, 2016), <https://doi.org/10.1371/journal.pone.0146392>.
44. Amir Kirolos et al., "Tuberculosis Case Notifications In Malawi Have Strong Seasonal And Weather-Related Trends," *Scientific Reports* 11, no. 4621 (February 2021), <https://doi.org/10.1038/s41598-021-84124-w>.
45. Valérie Schwœbel et al., "Outcomes of a Nine-Month Regimen for Rifampicin-Resistant Tuberculosis Up to 24 Months After Treatment Completion in Nine African Countries." *EClinicalMedicine* 20, no.100268 (February 2020), <https://doi.org/10.1016/j.eclinm.2020.100268>.
46. Knut Lönnroth et al., "Drivers of Tuberculosis Epidemics: The Role of Risk Factors and Social Determinants," *Social Science & Medicine* 68, no. 12 (April 23, 2009): 2240-2246, <https://doi.org/10.1016/j.socscimed.2009.03.041>.
47. Meredith B. Brooks et al., "Predictors of Unsuccessful Tuberculosis Treatment Outcomes in Children from a Prospective Cohort Study in Pakistan," *Journal of Global Health* 11, (February 2021), <https://doi:10.7189/jogh.11.04011>.
48. Muluken Berhanu Mena, Mohammed Gebre Dedefo, and Bruke Berhanu Billoro, "Treatment Outcome of Severe Acute Malnutrition and its Determinants Among Pediatric Patients in West Ethiopia," *International Journal of Pediatrics* 2018, Accessed January 27, 2021, <https://dx.doi.org/10.1155/2018/8686501>.
49. Sadick Ahmed Agyare et al., "Treatment Outcomes And Associated Factors In Tuberculosis Patients At Atwima Nwabiagya District, Ashanti Region, Ghana: A Ten-Year Retrospective Study," *Tuberculosis Research and Treatment*, Hindawi 2021, (July 2021): 1-9, <https://doi.org/10.1155/2021/9952806>.
50. Mario Raviglione et al., "Scaling up Interventions to Achieve Global Tuberculosis Control: Progress and New Developments," *The Lancet* 379, no. 9829 (June 15, 2012): 1902-1913, [https://doi.org/10.1016/s0140-6736\(12\)60727-2](https://doi.org/10.1016/s0140-6736(12)60727-2).
51. Blessing J. Akombi et al., "Child Malnutrition In Sub-Saharan Africa: A Meta-Analysis Of Demographic And Health Surveys (2006–2016)," *PLOS One* 12, no.5 (May 11, 2017), <https://doi.org/10.1371/journal.pone.0177338>.
52. Farhana Jabeen Shah et al., "Frequency of Sociodemographic Factors Leading to Pulmonary Tuberculosis in Diagnosed Patients Attending Public Health Care Facility," *Pakistan Journal of Medical and Health Sciences* 14, no. 4 (October 2020), https://pjmhsonline.com/2020/oct_dec/1173.pdf.
53. Brittny J. Sullivan, B. Emily Esmaili, and Coleen K. Cunningham, "Barriers To Initiating Tuberculosis Treatment In Sub-Saharan Africa: A Systematic Review Focused On Children And Youth," *Global Health Action* 10, no. 1 (2017), Accessed January 27, 2022, <https://doi.org/10.1080/16549716.2017.1290317>.
54. "Global Tuberculosis Report 2015," World Health Organization 2015, Accessed January 21, 2021, https://www.who.int/tb/publications/global_report/gtbr15_main_text.pdf.

55. Patrick Lungu et al., "Tuberculosis Care Cascade In Zambia - Identifying The Gaps In Order To Improve Outcomes: A Population-Based Analysis," . *BMJ Open* 2021, no. 11, Accessed January 27, 2022, <https://doi.org/10.1136/bmjopen-2020-044867>.
56. Amir Kirolos et al., "Tuberculosis Case Notifications In Malawi Have Strong Seasonal And Weather-Related Trends," *Scientific Reports* 11, no. 4621 (February 2021), <https://doi.org/10.1038/s41598-021-84124-w>.
57. Lambani Makwakwa et al., "Patient And Health System Delays In The Diagnosis And Treatment Of New And Retreatment Pulmonary Tuberculosis Cases In Malawi," *BMC Infectious Diseases* 14, no. 132 (2014), <https://doi.org/10.1186/1471-2334-14-132>.
58. Solomon A Yimer, Gunnar A. Bjune, and Carol Holm-Hansen, "Time To First Consultation, Diagnosis And Treatment Of Tb Among Patients Attending A Referral Hospital In Northwest, Ethiopia," *BMC Infectious Diseases* 14, no. 19 (2014), <https://doi.org/10.1186/1471-2334-14-19>.
59. Paul Waliaula Wekunda, Dickens S. Omondi Aduda, and Bernard Guyah, "Determinants Of Tuberculosis Treatment Interruption Among Patients In Vihiga County, Kenya," *PLOS One* 16, no.12 (Decemer 2, 2021), <https://doi.org/10.1371/journal.pone.0260669>.
60. Ramnath Subbaraman, Tulip Jhaveri, and Ruvandhi R. Nathavitharana, "Closing Gaps In The Tuberculosis Care Cascade: An Action-Oriented Research Agenda," *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases* 19, no. 100144 (May 2020), <https://doi.org/10.1016/j.jctube.2020.100144>.
61. Ndeindo Ndeikoundam Ngangro et al., "Pulmonary Tuberculosis Diagnostic Delays In Chad: A Multicenter, Hospital-Based Survey In Ndjamena And Moundou," *BMC Public Health* 12, no. 513 (July 9, 2012), <https://doi.org/10.1186/1471-2458-12-513>.
62. Ibrahim Sendagire et al., "Long Delays And Missed Opportunities In Diagnosing Smear-Positive Pulmonary Tuberculosis In Kampala, Uganda: A Cross-Sectional Study," *PLOS One* 5, no. 12 (December 29, 2010), <https://doi.org/10.1371/journal.pone.0014459>.
63. Lambani Makwakwa et al., "Patient And Health System Delays In The Diagnosis And Treatment Of New And Retreatment Pulmonary Tuberculosis Cases In Malawi," *BMC Infectious Diseases* 14, no. 132 (2014), <https://doi.org/10.1186/1471-2334-14-132>.
64. Ibrahim Sendagire et al., "Long Delays And Missed Opportunities In Diagnosing Smear-Positive Pulmonary Tuberculosis In Kampala, Uganda: A Cross-Sectional Study," *PLOS One* 5, no. 12 (December 29, 2010), <https://doi.org/10.1371/journal.pone.0014459>.
65. Lambani Makwakwa et al., "Patient And Health System Delays In The Diagnosis And Treatment Of New And Retreatment Pulmonary Tuberculosis Cases In Malawi," *BMC Infectious Diseases* 14, no. 132 (2014), <https://doi.org/10.1186/1471-2334-14-132>.
66. Christopher J. L. Murray et al., "Global, Regional, and National Incidence and Mortality for HIV, Tuberculosis, and Malaria during 1990-2013: A Systematic Analysis for the Global Burden of Disease Study 2013." *The Lancet* 384, no. 9947 (July 21, 2014) [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(14\)60844-8/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60844-8/fulltext)
67. Solomon A. Yimer, Gunnar A. Bjune, and Carol Holm-Hansen, "Time To First Consultation, Diagnosis And Treatment Of Tb Among Patients Attending A Referral Hospital In Northwest, Ethiopia," *BMC Infectious Diseases* 14, no. 19 (2014), <https://doi.org/10.1186/1471-2334-14-19>.
68. Brittney J. Sullivan, B. Emily Esmaili, and Coleen K. Cunningham, "Barriers To Initiating Tuberculosis Treatment In Sub-Saharan Africa: A Systematic Review Focused On Children And Youth," *Global Health Action* 10, no. 1 (2017), Accessed January 27, 2022, <https://doi.org/10.1080/16549716.2017.1290317>.
69. Jane M.Cramm et al., "Tb Treatment Initiation And Adherence In A South African Community Influenced More By Perceptions Than By Knowledge Of Tuberculosis," *BMC Public Health* 10, no. 72 (February 17, 2010), <https://doi.org/10.1186/1471-2458-10-72>.
70. Ibid.

71. Ramnath Subbaraman, Tulip Jhaveri, and Ruvandhi R. Nathavitharana, "Closing Gaps In The Tuberculosis Care Cascade: An Action-Oriented Research Agenda," *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases* 19, no. 100144 (May 2020), <https://doi.org/10.1016/j.jctube.2020.100144>.
72. Brittney J. Sullivan, B. Emily Esmaili, and Coleen K. Cunningham, "Barriers To Initiating Tuberculosis Treatment In Sub-Saharan Africa: A Systematic Review Focused On Children And Youth," *Global Health Action* 10, no. 1 (2017), Accessed January 27, 2022, <https://doi.org/10.1080/16549716.2017.1290317>.
73. Pren Naidoo et al., "The South African Tuberculosis Care Cascade: Estimated Losses And Methodological Challenges," *The Journal of Infectious Diseases* 216, no. 7 (November 6, 2017), <https://doi.org/10.1093/infdis/jix335>.
74. "Reported Tuberculosis in the United States, 2018," Centers for Disease Control and Prevention, Accessed Date January 27, 2022, <https://www.cdc.gov/tb/statistics/reports/2018/outcomes.htm>.
75. Ramnath Subbaraman et al., "Constructing Care Cascades For Active Tuberculosis: A Strategy For Program Monitoring And Identifying Gaps In Quality Of Care," *PLOS Medicine* 16, no. 2 (February 27, 2019), <https://doi.org/10.1371/journal.pmed.1002754>.
76. Pren Naidoo et al., "The South African Tuberculosis Care Cascade: Estimated Losses And Methodological Challenges," *The Journal of Infectious Diseases* 216, no. 7 (November 6, 2017), <https://doi.org/10.1093/infdis/jix335>.
77. Solomon A Yimer, Gunnar A. Bjune, and Carol Holm-Hansen, "Time To First Consultation, Diagnosis And Treatment Of Tb Among Patients Attending A Referral Hospital In Northwest, Ethiopia," *BMC Infectious Diseases* 14, no. 19 (2014), <https://doi.org/10.1186/1471-2334-14-19>.
78. [1] Sanctus Musafiri et al., "The Aftermath Of Pulmonary Tuberculosis: Predictors Of Severe Pulmonary Sequelae And Quality Of Life Of Patients Visiting A Tertiary Level Of Care In Rwanda, East Africa." *Austin J Pulm Respir Med* 2, no. 2 (September 4, 2015), <https://austinpublishinggroup.com/pulmonary-respiratory-medicine/fulltext/ajprm-v2-id1027.php>.
79. "The Difference Between Latent TB Infection and TB Disease," National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Center for Disease Control, Accessed January 21, 2022, <https://www.cdc.gov/tb/publications/factsheets/general/lbtbandactivetb.pdf>.
80. S.G. Mpagama et al., "The Burden And Determinants Of Post-Tb Lung Disease," *The International Journal of Tuberculosis and Lung Disease* 25, no. 10 (October 1, 2021): 846-853, <https://doi.org/10.5588/ijtld.21.0278>.
81. Jamilah Meghji et al., "Patient Outcomes Associated with Post-Tuberculosis Lung Damage in Malawi: A Prospective Cohort Study," *BMJ Journals* 75, no. 3 (March 4, 2020), <https://thorax.bmj.com/content/75/3/269>.
82. S.G. Mpagama et al., "The Burden And Determinants Of Post-Tb Lung Disease," *The International Journal of Tuberculosis and Lung Disease* 25, no. 10 (October 1, 2021): 846-853, <https://doi.org/10.5588/ijtld.21.0278>.
83. Sadick Ahmed Agyare et al., "Treatment Outcomes And Associated Factors In Tuberculosis Patients At Atwima Nwabiagya District, Ashanti Region, Ghana: A Ten-Year Retrospective Study," *Tuberculosis Research and Treatment*, Hindawi 2021, (July 2021): 1-9, <https://doi.org/10.1155/2021/9952806>.
84. Jamilah Meghji et al., "Patient Outcomes Associated with Post-Tuberculosis Lung Damage in Malawi: A Prospective Cohort Study," *BMJ Journals* 75, no. 3 (March 4, 2020), <https://thorax.bmj.com/content/75/3/269>.
85. A. T. Chin et al., "Chronic Lung Disease in Adult Recurrent Tuberculosis Survivors in Zimbabwe: A Cohort Study" HHS Public Access," *The International Journal of Tuberculosis and Lung Disease* 23, no. 2 (February 1, 2019): 203-211, <https://doi:10.5588/ijtld.18.0313>.

86. "Tuberculosis," Mayo Clinic, Accessed January 21, 2021, <https://www.mayoclinic.org/diseases-conditions/tuberculosis/symptoms-causes/syc-20351250>.
87. A. T. Chin et al., "Chronic Lung Disease in Adult Recurrent Tuberculosis Survivors in Zimbabwe: A Cohort Study" HHS Public Access," *The International Journal of Tuberculosis and Lung Disease* 23, no. 2 (February 1, 2019): 203-211, <https://doi:10.5588/ijtld.18.0313>.
88. Kamila Romanowski et al., "Long-Term all-Cause Mortality in People Treated for Tuberculosis: A Systematic Review and Meta-Analysis," *The Lancet Infectious Diseases* 19, no. 10 (July 16, 2019): 1129-1137, [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(19\)30309-3/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30309-3/fulltext).
89. A. T. Chin et al., "Chronic Lung Disease in Adult Recurrent Tuberculosis Survivors in Zimbabwe: A Cohort Study" HHS Public Access," *The International Journal of Tuberculosis and Lung Disease* 23, no. 2 (February 1, 2019): 203-211, <https://doi:10.5588/ijtld.18.0313>.
90. Anne Lia Cremers et al., "Assessing The Consequences Of Stigma For Tuberculosis Patients In Urban Zambia," *PLOS One* 10, no. 3 (March 25, 2015), <https://doi.org/10.1371/journal.pone.0119861>.
91. Andrew Courtwright and Abigail Norris Turner, "Tuberculosis and stigmatization: Pathways and interventions," *Public Health Reports*, July 1, 2010, <https://doi.org/10.1177/00333549101250S407>.
92. E. A. Dodor, K Neal, and S Kelly, "An Exploration Of The Causes Of Tuber-Culosis Stigma In An Urban District In Ghana," *The International Journal of Tuberculosis and Lung Disease* 12, no. 9 (September 2008): 1048-54, <https://pubmed.ncbi.nlm.nih.gov/18713503/>.
93. IA Abioye, MO Omotayo, and W Alakija, "Socio-Demographic Determinants Of Stigma Among Patients With Pulmonary Tuberculosis In Lagos, Nigeria," *African Health Sciences. African Journals Online* 11, (2011), <https://doi.org/10.4314/ahs.v11i3.70078>.
94. Ibid.
95. Sanctus Musafiri et al., "The Aftermath Of Pulmonary Tuberculosis: Predictors Of Severe Pulmonary Sequelae And Quality Of Life Of Patients Visiting A Tertiary Level Of Care In Rwanda, East Africa." *Austin J Pulm Respir Med* 2, no. 2 (September 4, 2015), <https://austinpublishinggroup.com/pulmonary-respiratory-medicine/fulltext/ajprm-v2-id1027.php>.
96. Ibid
97. Anne Lia Cremers et al., "Assessing The Consequences Of Stigma For Tuberculosis Patients In Urban Zambia," *PLOS One* 10, no. 3 (March 25, 2015), <https://doi.org/10.1371/journal.pone.0119861>.
98. Ibid.
99. Anteneh Asefa and Wondu Teshome, "Total Delay In Treatment Among Smear Positive Pulmonary Tuberculosis Patients In Five Primary Health Centers, Southern Ethiopia: A Cross Sectional Study," *PLOS One* 9, no. 7 (July 21, 2014), <https://doi.org/10.1371/journal.pone.0102884>.
100. Bereket Duko et al., "Perceived Stigma And Associated Factors Among Patient With Tuberculosis, Wolaita Sodo, Ethiopia: Cross-Sectional Study," *Tuberculosis Research and Treatment* 2019, (May 2, 2019), <https://doi.org/10.1155/2019/5917537>.
101. Steven Russell, "The Economic Burden Of Illness For Households In Developing Countries: A Review Of Studies Focusing On Malaria, Tuberculosis, And Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome," *The American Journal of Tropical Medicine and Hygiene* 71, no. 2, (January 2004): 147-155, <https://doi.org/10.4269/ajtmh.2004.71.147>.
102. Verena Mauch et al., "Assessing Access Barriers To Tuberculosis Care With The Tool To Estimate Patients' Costs: Pilot Results From Two Districts In Kenya," *BioMed Central Public Health* 11, no. 43 (January 18, 2011), <https://doi.org/10.1186/1471-2458-11-43>.

103. Steven Russell, "The Economic Burden Of Illness For Households In Developing Countries: A Review Of Studies Focusing On Malaria, Tuberculosis, And Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome," *The American Journal of Tropical Medicine and Hygiene* 71, no. 2, (January 2004): 147-155, <https://doi.org/10.4269/ajtmh.2004.71.147>.
104. Collins Timire et al., "Catastrophic Costs Among Tuberculosis-Affected Households In Zimbabwe: A National Health Facility-Based Survey," *Tropical Medicine & International Health*, June 30, 2021, <https://onlinelibrary.wiley.com/doi/full/10.1111/tmi.13647>.
105. "The World Bank in DRC," The World Bank, Accessed January 27, 2022, <https://www.worldbank.org/en/country/drc/overview#1>.
106. M. Kaswa et al., "The Economic Burden Of TB-Affected Households In DR Congo," *The International Journal of Tuberculosis and Lung Disease* 25, no. 11 (November 11, 2021): 923-932, <https://doi.org/10.5588/ijtld.21.0182>.
107. Samia Laokri et al., "Assessing The Economic Burden Of Illness For Tuberculosis Patients In Benin: Determinants And Consequences Of Catastrophic Health Expenditures And Inequities," *Tropical Medicine & International Health* 19, no. 10 (July 18, 2014), <https://doi.org/10.1111/tmi.12365>.
108. Steven Russell, "The Economic Burden Of Illness For Households In Developing Countries: A Review Of Studies Focusing On Malaria, Tuberculosis, And Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome," *The American Journal of Tropical Medicine and Hygiene* 71, no. 2, (January 2004): 147-155, <https://doi.org/10.4269/ajtmh.2004.71.147>.
109. N. A. Umar et al., "Direct Costs Of Pulmonary Tuberculosis Among Patients Receiving Treatment In Bauchi State, Nigeria," *The International Journal Of Tuberculosis And Lung Disease* 16, no. 6 (June 1, 2012): 835-840, <https://doi.org/10.5588/ijtld.10.0774>.
110. Collins Timire et al., "Catastrophic Costs Among Tuberculosis-Affected Households In Zimbabwe: A National Health Facility-Based Survey," *Tropical Medicine & International Health*, June 30, 2021, <https://onlinelibrary.wiley.com/doi/full/10.1111/tmi.13647>.
111. Verena Mauch et al., "Assessing Access Barriers To Tuberculosis Care With The Tool To Estimate Patients' Costs: Pilot Results From Two Districts In Kenya," *BioMed Central Public Health* 11, no. 43 (January 18, 2011), <https://doi.org/10.1186/1471-2458-11-43>.
112. Samia Laokri et al., "Assessing The Economic Burden Of Illness For Tuberculosis Patients In Benin: Determinants And Consequences Of Catastrophic Health Expenditures And Inequities," *Tropical Medicine & International Health* 19, no. 10 (July 18, 2014), <https://doi.org/10.1111/tmi.12365>.
113. Ndeindo Ndeikoundam Ngangro et al., "Pulmonary Tuberculosis Diagnostic Delays In Chad: A Multicenter, Hospital-Based Survey In Ndjamena And Moundou," *BMC Public Health* 12, no. 513 (July 9, 2012), <https://doi.org/10.1186/1471-2458-12-513>.
114. M. Kaswa et al., "The Economic Burden Of TB-Affected Households In DR Congo," *The International Journal of Tuberculosis and Lung Disease* 25, no. 11 (November 11, 2021): 923-932, <https://doi.org/10.5588/ijtld.21.0182>.
115. Steven Russell, "The Economic Burden Of Illness For Households In Developing Countries: A Review Of Studies Focusing On Malaria, Tuberculosis, And Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome," *The American Journal of Tropical Medicine and Hygiene* 71, no. 2, (January 2004): 147-155, <https://doi.org/10.4269/ajtmh.2004.71.147>.
116. Samia Laokri et al., "Assessing The Economic Burden Of Illness For Tuberculosis Patients In Benin: Determinants And Consequences Of Catastrophic Health Expenditures And Inequities," *Tropical Medicine & International Health* 19, no. 10 (July 18, 2014), <https://doi.org/10.1111/tmi.12365>.
117. Sachina Silva et al., "Economic Impact Of Tuberculosis Mortality In 120 Countries And The Cost Of Not Achieving The Sustainable Development Goals Tuberculosis Targets: A Full-Income

- Analysis," *The Lancet Global Health* 9, no. 10, (October 2021): e1372-e1379, [https://doi.org/10.1016/s2214-109x\(21\)00299-0](https://doi.org/10.1016/s2214-109x(21)00299-0).
118. Sachina Silva et al., "Economic Impact Of Tuberculosis Mortality In 120 Countries And The Cost Of Not Achieving The Sustainable Development Goals Tuberculosis Targets: A Full-Income Analysis," *The Lancet Global Health* 9, no. 10, (October 2021): e1372-e1379, [https://doi.org/10.1016/s2214-109x\(21\)00299-0](https://doi.org/10.1016/s2214-109x(21)00299-0).
119. "Guidelines on the Management of Latent Tuberculosis Infection," World Health Organization, Accessed January 22, 2022, https://apps.who.int/iris/bitstream/handle/10665/136471/9789241548908_%20eng.pdf?sequence=1#:~:text=Treatment%20options%20recommended%20for%20LTBI,to%20high%20quality%20of%20evidence).
120. A. T. Chin et al., "Chronic Lung Disease in Adult Recurrent Tuberculosis Survivors in Zimbabwe: A Cohort Study" HHS Public Access," *The International Journal of Tuberculosis and Lung Disease* 23, no. 2 (February 1, 2019): 203-211, <https://doi.org/10.5588/ijtld.18.0313>.
121. Ndivhuho A. Makhado et al., "Outbreak Of Multidrug-Resistant Tuberculosis In South Africa Undetected By Who-Endorsed Commercial Tests: An Observational Study," *The Lancet Infectious Diseases* 18, no. 12 (December 1, 2018): 1350-1359, [https://doi.org/10.1016/S1473-3099\(18\)30496-1](https://doi.org/10.1016/S1473-3099(18)30496-1).
122. "Guidelines For Treatment Of Drug-Susceptible Tuberculosis And Patient Care," World Health Organization, Accessed January 27, 2022, <https://apps.who.int/iris/bitstream/handle/10665/255052/9789241550000-eng.pdf>.
123. "Tuberculosis (TB) Adverse Events," Center for Disease Control and Prevention, Accessed August 15, 2021, <https://www.cdc.gov/tb/topic/treatment/adverseevents.htm>.
124. "Drugs and Supplements Rifampin (Oral Route)," Mayo Clinic, Accessed January 27, 2022, <https://www.mayoclinic.org/drugs-supplements/rifampin-oral-route/proper-use/drg-20065839>.
125. Meredith Milstein et al., "Evaluation Of High-Dose Rifampin In Patients With New, Smear-Positive Tuberculosis (Hirif): Study Protocol For A Randomized Controlled Trial," *BioMed Central Infectious Diseases* 16, no. 453 (August 27, 2016), <https://doi.org/10.1186/s12879-016-1790-x>.
126. Gustavo E. Velásquez et al., "Efficacy And Safety Of High-Dose Rifampin In Pulmonary Tuberculosis. A Randomized Controlled Trial," *American Journal of Respiratory and Critical Care Medicine*, Accessed January 22, 2022, <https://doi.org/10.1164/rccm.201712-2524oc>.
127. Elin M. Svensson et al., "The Potential For Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure To Treatment Response In Patients With Pulmonary Tuberculosis," *Clinical Infectious Diseases* 67, no. 1 (March 21, 2018): 34-41, <https://doi.org/10.1093/cid/ciy026>.
128. Yingjun Liu et al., "Optimal Doses Of Rifampicin In The Standard Drug Regimen To Shorten Tuberculosis Treatment Duration And Reduce Relapse By Eradicating Persistent Bacteria," *Journal of Antimicrobial Chemotherapy* 73, no. 1 (March 2018): 724-731, <https://doi.org/10.1093/jac/dkx467>.
129. Ibid.
130. Elin M. Svensson et al., "The Potential For Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure To Treatment Response In Patients With Pulmonary Tuberculosis," *Clinical Infectious Diseases* 67, no. 1 (March 21, 2018): 34-41, <https://doi.org/10.1093/cid/ciy026>.
131. Yingjun Liu et al., "Optimal Doses Of Rifampicin In The Standard Drug Regimen To Shorten Tuberculosis Treatment Duration And Reduce Relapse By Eradicating Persistent Bacteria," *Journal of Antimicrobial Chemotherapy* 73, no. 1 (March 2018): 724-731, <https://doi.org/10.1093/jac/dkx467>.

